Core Viewpoint - MBX Biosciences, Inc. (MBX) has shown significant stock price appreciation of 74.8% over the past four weeks, with a mean price target of $58.25 indicating a potential upside of 142% from the current price of $24.07 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $16.63, suggesting variability in analyst predictions. The lowest estimate is $30.00, indicating a 24.6% increase, while the highest estimate is $80.00, suggesting a 232.4% increase [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism regarding MBX's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 2.7% over the past month, with three estimates increasing and no negative revisions [12] - MBX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - While consensus price targets are often sought after, they can mislead investors, as empirical research shows that they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10][14]

Core Viewpoint - Electromed, Inc. (ELMD) shares have increased by 8.4% in the past four weeks, closing at $26.35, with a potential upside of 39.2% based on Wall Street analysts' mean price target of $36.67 [1][4]. Price Targets - The average price target for ELMD ranges from a low of $36.00 to a high of $38.00, with a standard deviation of $1.15, indicating a relatively tight clustering of estimates [2][9]. - The lowest estimate suggests a 36.6% increase from the current price, while the highest estimate indicates a 44.2% upside [2]. Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which historically correlates with positive stock price movements [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 2.9%, with two estimates moving higher and no negative revisions [12]. Zacks Rank - ELMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a solid potential upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of the exact price movement, it does provide a useful directional guide for potential stock performance [14].

Core Viewpoint - Gen Digital (GEN) shows potential for significant upside, with a mean price target of $34.38 indicating a 28.7% increase from its current price of $26.72 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.5, suggesting variability in analyst predictions. The lowest estimate is $29.00 (8.5% increase), while the highest is $46.00 (72.2% increase) [2][9]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown growing optimism regarding GEN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. This correlation between earnings revisions and stock price movements supports the expectation of an upside [11][12]. - Over the past 30 days, the Zacks Consensus Estimate for the current year has increased by 1.3%, with one estimate moving higher and no negative revisions [12]. Zacks Rank and Investment Potential - GEN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]. - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14].

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) shows potential for significant upside, with a mean price target of $11.1 indicating a 75.1% increase from its current price of $6.34 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.47, suggesting variability in analyst predictions. The lowest estimate is $6.58 (3.8% increase), while the highest is $14.00 (120.8% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about EPRX's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two EPS estimates have increased while one has decreased, leading to a 16.1% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable measure of potential gains, it does provide a useful guide for price movement direction [14]

Core Insights - Target (TGT) is expected to report quarterly earnings of $1.76 per share, reflecting a decline of 4.9% year-over-year, with revenues projected at $25.36 billion, down 1.2% from the previous year [1] - The consensus EPS estimate has been revised downward by 0.9% in the last 30 days, indicating a reassessment by analysts [1][2] Revenue Estimates - Analysts estimate 'Net Sales- Merchandise sales- Beauty & household essentials' at $3.16 billion, a significant decline of 60.4% year-over-year [4] - The 'Net Sales- Merchandise sales- Food & beverage' is forecasted at $5.88 billion, showing a slight decrease of 0.6% from the previous year [4] - 'Net Sales- Merchandise sales- Hardlines' is projected to reach $3.10 billion, indicating a decline of 1.5% year-over-year [5] - 'Net Sales- Merchandise sales- Other' is expected to be $29.91 million, down 0.3% from the year-ago quarter [5] Store and Retail Space Metrics - The total number of stores is estimated to be 1,988, an increase from 1,978 a year ago [5] - Total retail square footage is projected at 250 million square feet, up from 248 million square feet year-over-year [6] - Retail square footage for stores between 50,000 to 169,999 sq. ft is expected to reach 196 million square feet, compared to 195 million square feet last year [6] Comparable Sales and Digital Metrics - 'Digitally Originated Comparable Sales Change' is expected to be 4.9%, down from 10.8% in the same quarter last year [7] - The number of stores under 49,999 sq. ft is projected to be 149, up from 146 in the same quarter last year [8] - The number of stores between 50,000 to 169,999 sq. ft is estimated at 1,566, an increase from 1,559 year-over-year [8] - The number of stores 170,000 sq. ft or more is expected to remain at 273, unchanged from the previous year [9] Stock Performance - Over the past month, Target shares have returned +0.6%, compared to a +1.4% change in the Zacks S&P 500 composite [9]

Core Viewpoint - The Pennant Group, Inc. (PNTG) shows potential for significant upside, with a mean price target of $33 indicating a 30.7% increase from the current price of $25.25 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $4.82, suggesting variability among analysts [2] - The lowest estimate is $28.00, indicating a 10.9% increase, while the highest estimate is $40.00, suggesting a 58.4% increase [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about PNTG's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.6%, with two estimates moving higher and no negative revisions [12] - PNTG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Ategrity Specialty Insurance Company Holdings (ASIC) closed the last trading session at $18.29, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.8 indicates a 41.1% upside potential.The average comprises five short-term price targets ranging from a low of $23.00 to a high of $30.00, with a standard deviation of $2.95. While the lowest estimate indicates an increase ...

Core Insights - Klaviyo, Inc. (KVYO) is experiencing solid improvement in earnings estimates, indicating a positive outlook for the stock [1][2] - The upward trend in estimate revisions reflects growing analyst optimism, which is expected to influence the stock price positively [2][3] Current-Quarter Estimate Revisions - The expected earnings for the current quarter are $0.17 per share, representing a year-over-year increase of +142.9% [5] - The Zacks Consensus Estimate for Klaviyo has risen by 80% over the last 30 days, with five estimates increasing and no negative revisions [5] Current-Year Estimate Revisions - For the full year, the expected earnings are $0.65 per share, reflecting a +30.0% change from the previous year [6] - Over the past month, seven estimates have been revised upward, contributing to a consensus estimate increase of 191.67% [6][7] Zacks Rank - Klaviyo, Inc. has achieved a Zacks Rank 2 (Buy), indicating strong agreement among analysts regarding positive earnings revisions [8] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [8] Bottom Line - The strong estimate revisions have led to a 20.7% increase in the stock price over the past four weeks, suggesting potential for further upside [9]

Core Viewpoint - Expeditors International (EXPD) shows potential as a strong investment opportunity due to significant upward revisions in earnings estimates, indicating improving earnings outlook and stock performance [1][10]. Earnings Estimate Revisions - The current quarter's earnings estimate is projected at $1.44 per share, reflecting a decrease of 14.3% from the previous year, but has seen a 13.25% increase in consensus estimates over the last 30 days with four upward revisions and no negative changes [6]. - For the full year, the earnings estimate stands at $5.85 per share, which is a 2.3% increase from the prior year, supported by six upward revisions and no negative revisions, leading to a 6.61% increase in consensus estimates [7][8]. Analyst Sentiment - There is a strong consensus among analysts regarding the upward revision of earnings estimates for Expeditors International, contributing to a favorable outlook for the company [3][9]. - The Zacks Rank system, which categorizes stocks from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Expeditors International as 1, indicating strong buy sentiment based on the positive estimate revisions [9]. Stock Performance - The stock has experienced an 18.8% gain over the past four weeks, driven by the positive earnings growth prospects, suggesting continued upward momentum [10].

DIRTT Environmental Solutions Ltd. (DRTTF) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. ...